Okroj Marcin, Spiller O Brad, Korodi Zoltan, Tedeschi Rosamaria, Dillner Joakim, Blom Anna M
Department of Laboratory Medicine, Lund University, University Hospital Malmö, S-205 02 Malmö, Sweden.
Vaccine. 2007 Nov 23;25(48):8102-9. doi: 10.1016/j.vaccine.2007.09.046. Epub 2007 Oct 9.
Kaposi sarcoma-associated herpesvirus (KSHV) is the most important etiopathological factor of Kaposi's sarcoma (KS) and some specific types of malignant lymphomas. One of the viral lytic genes encodes the KSHV complement control protein (KCP), which functionally mimics human complement inhibitors. Although this protein provides an advantage for evading the complement attack, it can serve as target for adaptive immune response. Herein, we identified anti-KCP IgG antibodies in patients with KS and KSHV-related lymphomas. KCP-specific antibodies were only detected in sera of those patients who had high titres of antibodies against lytic or latent KSHV antigens. Complement control protein domain 2 (CCP2) was found to be the most immunogenic part of the KCP protein. Furthermore, pre-incubation of KCP-expressing CHO cells with patient sera containing anti-KCP antibodies resulted in an increased complement deposition when incubated with human serum.
卡波西肉瘤相关疱疹病毒（KSHV）是卡波西肉瘤（KS）和某些特定类型恶性淋巴瘤最重要的病因病理因素。该病毒的一种裂解基因编码KSHV补体控制蛋白（KCP），其在功能上模拟人类补体抑制剂。尽管这种蛋白为逃避补体攻击提供了优势，但它可成为适应性免疫反应的靶点。在此，我们在KS患者和KSHV相关淋巴瘤患者中鉴定出了抗KCP IgG抗体。仅在那些针对裂解或潜伏KSHV抗原具有高滴度抗体的患者血清中检测到KCP特异性抗体。补体控制蛋白结构域2（CCP2）被发现是KCP蛋白中最具免疫原性的部分。此外，用含有抗KCP抗体的患者血清对表达KCP的CHO细胞进行预孵育后，再与人血清孵育会导致补体沉积增加。
